Infectologia
Teste de suscetibilidade antifúngica: uma introdução para clínicos.
14 Set, 2021 | 14:12hAntifungal Susceptibility Testing: A Primer for Clinicians – Open Forum Infectious Diseases
Comentário no Twitter
New in OFID: An overview for clinicians on antifungal susceptibility testing, including testing methods and their limitations, and how results may or may not be clinically useful.
📄:https://t.co/ZhPL5oQ57F #OpenForumInfectDis #IDSAJournals @PaulSaxMD @DrJLi pic.twitter.com/wrIkBc5MPV
— IDSA (@IDSAInfo) September 11, 2021
Qual é a evidência para as doses de reforço contra COVID-19?
12 Set, 2021 | 22:23hWhat’s the evidence for COVID-19 booster shots? – Canadian Medical Association Journal
Risco de Covid-19 severa em indivíduos já vacinados é maior para idosos e pessoas com condições subjacentes.
12 Set, 2021 | 22:22hRisk of severe breakthrough Covid-19 higher for seniors and people with underlying conditions – CNN
Estudo original: Hospitalisation among vaccine breakthrough COVID-19 infections – The Lancet Infectious Diseases
Comunicado de imprensa: Study examines severe breakthrough cases of COVID-19 – YaleNews
Comentário no Twitter
New Comment: Hospitalisation among vaccine breakthrough #COVID19 infections https://t.co/1MtOoO8HVV, by Prerak V Juthani, @hyungjchun, and colleagues pic.twitter.com/mYAAEzHLDL
— The Lancet Infectious Diseases (@TheLancetInfDis) September 8, 2021
Quatro fatores que aumentam o risco de pessoas vacinadas contraírem COVID.
12 Set, 2021 | 22:20hFour factors that increase the risk of vaccinated people getting COVID – The Conversation
Perspectiva | Estamos pedindo o impossível às vacinas – “Há muito tempo, a proteção completa contra infecções tem sido aclamada como o “Santo Graal” da vacinação. Pode ser que isso seja simplesmente inalcançável.”
12 Set, 2021 | 22:19hWe’re Asking the Impossible of Vaccines – The Atlantic
Comentário no Twitter
A really great read from @KatherineJWu on why it may be too much to expect vaccines—#covid19 or otherwise—to prevent infection. Still the vaccines are great at what we need—preventing hospitalizations and deaths! https://t.co/ufVBVn4wd1
— Jennifer Nuzzo, DrPH (@JenniferNuzzo) September 11, 2021
Perspectiva | Como tornar a pandemia de COVID um risco gerenciável – “Negócios e escolas devem se adaptar, porque a dupla ameaça do coronavírus e da gripe também será grave.”
12 Set, 2021 | 22:17hHow Endemic COVID Becomes a Manageable Risk – The Atlantic
Comentário no Twitter
.@TheAtlantic /@ScottGottliebMD — How Endemic COVID Becomes a Manageable Risk/We’re not going to annihilate COVID. Instead, our goal must be to weaken its punch so that it becomes a risk we can adapt to. https://t.co/TEX5kxBMO2
— Greg Folkers (@greg_folkers) September 12, 2021
A variante Delta da Covid e crianças: relatório mostra que a transmissão em crianças é baixa e somente 2% delas são hospitalizadas.
12 Set, 2021 | 22:16hComunicado de imprensa: COVID-19 Delta variant in schools and early childhood education and care services in NSW, Australia: 16 June to 31 July 2021
Comentário no Twitter (fio – clique para saber mais)
Amazing education settings outbreak data from the Delta #COVID19 outbreak in NSW 🇦🇺
Primary/Secondary schools mostly closed, so limited info to draw on (Attack rate v low, <2%)
BUT early years settings fully open with no masks!
What happened? 🧵https://t.co/mG05e5Mp3T
1/
— Alasdair Munro (@apsmunro) September 8, 2021
Estudo de coorte | Seguimento de longo prazo mostrou que a maioria das crianças com síndrome inflamatória multissistêmica pós-COVID-19 teve bons desfechos, sem sequelas significativas no médio ou no longo prazo.
12 Set, 2021 | 22:14hComentário: Outcome Good at One Year for Majority of PIMS-TS Patients – HealthDay
Comentário no Twitter
A new study reports that a small number of pediatric patients are at risk for poor long-term outcomes of multisystem inflammatory syndrome in children. https://t.co/rUk4YEGRin pic.twitter.com/CgBi33Mzd5
— JAMA Pediatrics (@JAMAPediatrics) September 2, 2021
Estudo randomizado | Plasma convalescente não melhora os desfechos e pode ser prejudicial a pacientes hospitalizados com COVID-19.
12 Set, 2021 | 21:56hComunicado de imprensa: Major study finds convalescent plasma doesn’t help seriously ill COVID-19 patients – McMaster University
Conteúdos relacionados:
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
Comentário no Twitter
A randomized trial in patients hospitalized with COVID-19 showed no benefit and potentially increased harm associated with the use of convalescent plasma, according to a @NatureMedicine paper. https://t.co/7JFhEXLmbA pic.twitter.com/Q3e50Q0I7T
— Nature Portfolio (@NaturePortfolio) September 9, 2021
Máscaras contra COVID passam em seu maior teste – “Um estudo rigoroso mostra que máscaras cirúrgicas são altamente protetoras, mas máscaras de tecido, nem tanto.”
12 Set, 2021 | 21:54hFace masks for COVID pass their largest test yet – Nature
Estudo original: [Preprint] Largest study of masks yet details their importance in fighting Covid-19.
Comentário no Twitter
Face masks for COVID pass their largest test yet – I & others comment. It is true that I bought pink surgical masks (my favorite color) in response to this study for when I am around unvaccinated adults (or indoor public spaces for now)https://t.co/nFhlcqwrjv
— Monica Gandhi MD, MPH (@MonicaGandhi9) September 9, 2021